Table 1 Baseline characteristics for patients receiving high-potency statins
From: Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus
Patients with diabetes (n = 276) | Patients without diabetes (n = 659) | |||||||
|---|---|---|---|---|---|---|---|---|
Atorvastatin | Pitavastatin | Rosuvastatin | P-value | Atorvastatin | Pitavastatin | Rosuvastatin | p-value | |
Number of patients | 87 | 70 | 119 | - | 221 | 151 | 287 | - |
Mean follow-up days | 262 | 313 | 303 | 0.60 | 243 | 314 | 352 | 0.01 |
Male, % | 75.9 | 65.7 | 62.2 | 0.11 | 52.0 | 53.0 | 57.5 | 0.43 |
Age, years, mean ± SD | 66.2 ± 11 | 65.8 ± 12 | 67.5 ± 12 | 0.56 | 68.1 ± 11 | 67.4 ± 11 | 66.0 ± 12 | 0.12 |
Disease, % | ||||||||
Diabetes | 96.6 | 97.1 | 97.4 | 0.93 | 0 | 0 | 0 | - |
Hypertension | 72.4 | 57.1 | 70.6 | 0.09 | 48.4 | 58.3 | 55.0 | 0.30 |
Myocardial infarction | 12.6 | 11.4 | 18.5 | 0.33 | 17.6 | 17.2 | 19.5 | 0.80 |
Chronic heart failure | 18.4 | 14.3 | 21.0 | 0.52 | 16.7 | 17.2 | 22.0 | 0.27 |
Renal disease | 12.6 | 5.7 | 16.0 | 0.12 | 11.7 | 17.9 | 10.8 | 0.09 |
Liver disease | 8.0 | 8.6 | 11.8 | 0.63 | 9.5 | 7.3 | 13.6 | 0.10 |
Pulmonary disease | 13.8 | 14.3 | 12.6 | 0.94 | 14.9 | 13.2 | 19.1 | 0.22 |
CCI, mean | 1.3 | 1.4 | 1.3 | 0.50 | 1.2 | 1.3 | 1.3 | 0.88 |
Concomitant medications, % | ||||||||
Antidiabetics (insulin) | 86.2 (10.3) | 81.4 (10.0) | 80.7 (8.6) | 0.56 | 0 | 0 | 0 | - |
ACEIs or ARBs | 47.1 | 47.1 | 47.1 | 0.99 | 35.3 | 40.4 | 33.8 | 0.39 |
Beta-blockers | 25.3 | 10.0 | 31.9 | 0.003 | 21.2 | 26.5 | 22.0 | 0.45 |
Thiazides | 4.6 | 8.6 | 6.8 | 0.60 | 4.5 | 1.3 | 5.9 | 0.08 |
CCBs | 39.1 | 28.6 | 41.1 | 0.21 | 43.0 | 34.4 | 31.7 | 0.03 |
Antipsychotics | 0 | 0 | 4.2 | 0.03 | 3.2 | 3.3 | 1.7 | 0.49 |
Laboratory tests | ||||||||
HbA1c, %, mean (n) | 6.9 (74) | 7.3 (58) | 7.0 (97) | 0.14 | 5.7 (115) | 5.8 (72) | 5.8 (153) | 0.67 |
Ordering Llipids, % | 92.0 | 94.3 | 93.3 | 0.85 | 86.9 | 83.4 | 86.8 | 0.58 |